EssilorLuxottica stock holds buyback support as Q2 2026 revenue grows

EssilorLuxottica stock is trading well below its 2026 start despite ongoing share buybacks and rising Q2 2026 revenue, leaving investors focused on how capital returns and growth balance out.

EssilorLuxottica stock (FR0000033219) remains under pressure despite solid operating momentum, with the EssilorLuxottica American depositary receipt ESLOY closing at 92.79 USD as of August 31, 2026 on the US over-the-counter market according to recent quote data, implying a market capitalization of about 86.15 billion USD and a year-to-date decline of 41.4 percent from a starting 2026 level of 158.42 USD per share as highlighted by a recent EssilorLuxottica-focused market overview on ad-hoc-news.de. For DACH investors, the company is also tradable on European venues that participate in the group’s ongoing share buyback framework, which continues to underpin the stock alongside recent revenue growth in the latest quarter.

Q2 2026 revenue trend and buyback details

According to a recent analysis of EssilorLuxottica’s latest interim figures summarized in an EssilorLuxottica corporate update on ad-hoc-news.de, the company reported revenue growth in Q2 2026 compared with the prior-year quarter, confirming that demand in its eyewear and lens businesses is still expanding. The same overview points out that EssilorLuxottica has combined this top-line expansion with continued capital returns via share repurchases, which aim to reduce the share count and support earnings per share over time based on the company’s stated capital allocation framework.

Fresh disclosures referenced by a news item on StockTitan indicate that between August 17 and August 21, 2026, EssilorLuxottica repurchased 137,964 shares at a daily weighted average price of 159.8694 EUR across several European trading venues, in line with its authorized buyback program that targets a portion of outstanding capital to be retired over time. This concrete tranche confirms that the buyback has remained active into late August 2026, which, at least in principle, provides a mechanical support for earnings per share by spreading profits over a smaller share base even if the headline share price has corrected significantly year to date.

Analyst and consensus signals for EssilorLuxottica stock

A recent markets piece hosted by The Globe and Mail citing TipRanks data notes that the most recent analyst view on EssilorLuxottica’s FR:EL listing is categorized as a Hold, indicating that the covering analysts currently see neither a strong buy nor an outright sell case at prevailing levels. The same source highlights that, alongside the Hold stance, analysts continue to monitor how the combination of revenue growth in Q2 2026 and the ongoing share buyback program will translate into future earnings per share, especially given the sharp drawdown in the stock compared with the start of 2026 and the implied compression in valuation multiples.

The contrast between the company’s ongoing buybacks and the depressed share price is evident when comparing the ESLOY closing level of 92.79 USD as of August 31, 2026 with the start-of-year level of 158.42 USD from the same ad-hoc-news.de market overview, a decline of 41.4 percent year to date. This quantified drop suggests that, despite supportive actions such as the 137,964-share buyback tranche executed between August 17 and August 21, 2026 described in the StockTitan disclosure, investors have continued to re-rate the stock downward, likely reflecting concerns about macroeconomic conditions, discretionary consumer spending on eyewear and broader equity market volatility rather than a collapse in EssilorLuxottica’s reported revenue trajectory.

Product focus: flagship lenses and frames

EssilorLuxottica is known for combining premium eyewear brands with advanced lens technologies, and recent trade coverage on Eyes On Eyecare highlights how the group’s custom contact lens activities continue to evolve. In that report, X-Cel Specialty Contacts and Essilor Custom Contacts, a unit of EssilorLuxottica, are described as collaborating to introduce a new overnight orthokeratology lens called Lunara to the US commercial market, with promotional incentives such as a 50 percent discount for US practices on Lunara orders through December 31, 2026. This illustrates how EssilorLuxottica leverages both frames and specialty lens products to expand its offering beyond traditional spectacles into areas such as overnight ortho-k lenses that reshape the cornea while patients sleep.

EssilorLuxottica stock price context for investors

As of the most recent completed trading session on August 31, 2026, the EssilorLuxottica American depositary receipt ESLOY closed at 92.79 USD on the US over-the-counter market based on the EssilorLuxottica quote overview cited by ad-hoc-news.de, implying a market capitalization of about 86.15 billion USD and a year-to-date decline of 41.4 percent from a starting 2026 level of 158.42 USD per share. For investors, this means that EssilorLuxottica stock is now trading far below its 2026 opening price even though the company has reported revenue growth in Q2 2026 and continues to execute share buybacks such as the 137,964-share tranche between August 17 and August 21, 2026 outlined in the StockTitan disclosure, a juxtaposition that underscores how sentiment and valuation, rather than only reported figures, are driving the share price.

EssilorLuxottica stock key data

• Company: EssilorLuxottica S.A.
• ISIN: FR0000033219
• Ticker: ESLOY
• Trading venue: OTC (United States) via American depositary receipt
• Price (as of August 31, 2026, 15:56): 92.79 USD
• Market capitalization: 86.15 billion USD (as of August 31, 2026)
• Sector / Industry: Consumer Discretionary / Specialty Retail - Eyewear
• Index membership: CAC 40